Domov › Steatotična bolezen jeter › North Carolina
Klinične študije za Steatotična bolezen jeter v North Carolina
13 študij za Steatotična bolezen jeter išče udeležence na lokacijah v North Carolina.
Mesta v North Carolina
Uradno besedilo študije (angleško)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Asheville
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- in še 2
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Charlotte
- 89bio Clinical Study Site, Durham
- 89bio Clinical Study Site, Fayetteville
- in še 3
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Morehead City
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- Duke Liver Center, Durham
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05832229A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Duke University - Main Hospital and Clinics, Durham
- Monroe Biomedical Research, Monroe
- Carteret Medical Group, Morehead City
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Chapel Hill
- Akero Clinical Study Site, Charlotte
- Akero Clinical Study Site, Charlotte
- in še 5
Vključevanje udeležencevFaza 3
Starost 18–80 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Morehead City
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Coastal Research Institute, Fayetteville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Morehead City
Vključevanje udeležencevFaza 3
Starost 18–75 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Fayetteville
- GSK Investigational Site, Wilson
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT06920043Androgens and NAFLD Longitudinal Cohort Study
- Duke University, Durham
Vključevanje udeležencevOpazovalna študija
Starost 18–42 · Ženske · Posodobljeno 13. apr. 2026 · NCT06124261Siemens Biomarker Multi-modality
- Duke University Medical Center, Durham
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 3. apr. 2026 · NCT07495332Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.